Carfilzomib produces OS benefit vs. bortezomib in relapsed, refractory disease

Elrexfio produces median OS of >2 two years in R/R MM in single-arm phase II study

The phase II MagnetisMM-3 study of Elrexfio (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.

June 21, 2024

Vol.50 No.25

Clinical Trials & Tribulations

The thorny road to drug approval for myelodysplastic syndromes

At the recent ASCO annual meeting, within hematologic malignancies, therapies for multiple myeloma stole the show, comme d’habitude.

June 14, 2024

Vol.50 No.24

By Mikkael A. Sekeres

Clinical Roundup

Sarclisa combination improves PFS in newly diagnosed transplant-ineligible MM in phase III trial

Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone followed by Sarclisa-Rd (the IMROZ regimen) significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly diagnosed multiple myeloma not eligible for transplant.

June 07, 2024

Vol.50 No.23

Regulatory News

ODAC unanimously upholds MRD as early endpoint across all settings in multiple myeloma

In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.

April 26, 2024

Vol.50 No.17

By Jacquelyn Cobb

Conversation with The Cancer Letter

Clearing the path for MRD as early endpoint in multiple myeloma

Sylvester’s C. Ola Landgren: “I was convinced that this is really the way to go”

Black patients with multiple myeloma aren’t getting autoHCT as often as others—and the disparity has widened

Black patients are less likely than patients of other races and ethnicities to receive autologous hematopoietic cell transplants for multiple myeloma, according to a study published in the April issue of Clinical Lymphoma, Myeloma, and Leukemia.

April 26, 2024

Vol.50 No.17

By McKenzie Prillaman

Carfilzomib produces OS benefit vs. bortezomib in relapsed, refractory disease

YOU MAY BE INTERESTED IN

Elrexfio produces median OS of >2 two years in R/R MM in single-arm phase II study

The thorny road to drug approval for myelodysplastic syndromes

Sarclisa combination improves PFS in newly diagnosed transplant-ineligible MM in phase III trial

ODAC unanimously upholds MRD as early endpoint across all settings in multiple myeloma

Clearing the path for MRD as early endpoint in multiple myeloma

Black patients with multiple myeloma aren’t getting autoHCT as often as others—and the disparity has widened

Renew today!

Subscriber content

Login